The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response

Development of novel antibodies to combat the novel SARS-CoV-2 virus is ongoing. Importantly, particular subgroups are more prone to severe disease, namely patients with poor immune responses. This includes cancer patients with solid and haematological disease, solid organ transplant (SOT) patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Migo, William, Boskovic, Marko, Likic, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
COVID-19 therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501196/
https://www.ncbi.nlm.nih.gov/pubmed/34870159
http://dx.doi.org/10.1016/j.crphar.2021.100064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501196/
https://www.ncbi.nlm.nih.gov/pubmed/34870159
http://dx.doi.org/10.1016/j.crphar.2021.100064

Ejemplares similares